PRW Wealth Management’s Novartis NVS Stock Holding History

PRW Wealth Management’s Portfolio NVS Stock Details NVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$383K	Hold	4,083	–	–	0.15%	58
2023 Q2	$404K	Buy	+4,083	New	+$408K	0.14%	39
2021 Q3	–	Sell	-14,421	Closed	-$1.32M	–	229
2021 Q2	$1.32M	Buy	+14,421	New	+$1.28M	0.39%	81

Other funds holding NVS

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

PRW Wealth Management's NVS Position: Q3 2023 in Review

PRW Wealth Management held its Novartis (NVS) position steady in Q3 2023 at 4,083 shares worth $383K. The position accounts for 0.15% of the portfolio, ranked #58.

PRW Wealth Management first reported a position in NVS in Q2 2021 and has held it in 3 quarters since. The position peaked at $1.32M in Q2 2021. 1,222 funds tracked by Wall St. Rank hold NVS as of Q3 2023.

PRW Wealth Management held 4,083 shares of Novartis worth $383K as of Q3 2023.
PRW Wealth Management left its Novartis share count unchanged in Q3 2023.
Novartis made up 0.15% of PRW Wealth Management's portfolio in Q3 2023, its #58 holding.
PRW Wealth Management first reported a position in Novartis in Q2 2021 and has held it in 3 quarters since.
PRW Wealth Management's Novartis position peaked at $1.32M in Q2 2021.
1,222 funds tracked by Wall St. Rank held Novartis as of Q3 2023.

Based on PRW Wealth Management's 13F filing for Q3 2023, filed 1 Nov 2023.